Study design and rationale of EXPLORER-CN: a phase III, randomised, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of mavacamten in Chinese adults with symptomatic obstructive hypertrophic cardiomyopathy
- DOI
- 10.1136/bmjopen-2022-071473
- Published
- 2023-06
- Container
- BMJ Open
- Publisher
- BMJ
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1136/bmjopen-2022-071473,
title = {Study design and rationale of EXPLORER-CN: a phase III, randomised, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of mavacamten in Chinese adults with symptomatic obstructive hypertrophic cardiomyopathy},
author = {Zhuang Tian and Fang Wang and Wei Jin and Qing Zhang and Jingmin Zhou and Ping Yang and Geng Wang and Peiwen Hsu and Jing Sun and Shuyang Zhang and Yaling Han},
year = {2023},
journal = {BMJ Open},
doi = {10.1136/bmjopen-2022-071473},
url = {https://doi.org/10.1136/bmjopen-2022-071473}
}RIS
TY - JOUR TI - Study design and rationale of EXPLORER-CN: a phase III, randomised, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of mavacamten in Chinese adults with symptomatic obstructive hypertrophic cardiomyopathy AU - Zhuang Tian AU - Fang Wang AU - Wei Jin AU - Qing Zhang AU - Jingmin Zhou AU - Ping Yang AU - Geng Wang AU - Peiwen Hsu AU - Jing Sun AU - Shuyang Zhang AU - Yaling Han PY - 2023 JO - BMJ Open DO - 10.1136/bmjopen-2022-071473 UR - https://doi.org/10.1136/bmjopen-2022-071473 ER -
APA
Tian, Z., Wang, F., Jin, W., Zhang, Q., Zhou, J., Yang, P., Wang, G., Hsu, P., Sun, J., Zhang, S., & Han, Y. (2023). Study design and rationale of EXPLORER-CN: a phase III, randomised, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of mavacamten in Chinese adults with symptomatic obstructive hypertrophic cardiomyopathy. BMJ Open. https://doi.org/10.1136/bmjopen-2022-071473
Source records
- crossref · retrieved 2026-09-26T02:41:04.439Z